Referenties
1Grond S et al. Assessment of cancer pain: a prospective evaluation in 2266 cancer patients referred to a pain service. Pain. 1996;64(1):107–14.
2Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI. on behalf of the ESMO Guidelines Committee Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Annals of Oncology 2018;29(Supplement_4): iv166-iv91.
3Smith TJ, Staats PS, Deer T, et al. Randomized clinical trial of an implantable drug delivery (IDDS) system compared with comprehensive medical management (CMM) for refractory cancer pain: impact on pain, drug-related toxicity, and survival. J Clin Oncol. 2002;20(19):4040–9.
4Smith TJ, Coyne PJ. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients. J Palliat Med. 2005;8(4):736–42.
5Mishra S, Bhatnagar S, Chaudhary P, Pratap Singh Rana S. Breakthrough Cancer Pain: Review of Prevalence, Characteristics and Management. Indian J Palliat Care. 2009 Jan-Jun; 15(1): 14–18.
6Davies AN, Dickman A, Reid C, Stevens A-M, Zeppetella G. The management of cancer-related breakthrough pain: Recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland. European Journal of Pain 2009;13(4): 331-38.
7Stearns L, Abd-Elsayed A, Perruchoud C, et. al. Intrathecal drug delivery systems for cancer pain: an analysis of a prospective, multicenter product surveillance registry. Anesth Analg. 2020 Feb;130(2):289-297.
9Landelijke richtlijn Pijn bij patiënten met kanker, versie 3.0, 2019
13Brogan E, Winter NB, Okifuji A. Prospective Observational Study of Patient-Controlled Intrathecal Analgesia: Impact on Cancer-Associated Symptoms, Breakthrough Pain Control, and Patient Satisfaction. Reg Anesth Pain Med. 2015;40(4):369–75.
15Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer. 2018 Nov;103:356-387.
16Breivik H, Cherny N, Collett B, et al. Cancerrelated pain: a pan-European survey of prevalence, treatment, and patient attitudes. Annals of Oncology 2009;20(8): 1420-33.
17Van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, et al. Update on Prevalence of Pain in Patients With Cancer: Systematic Review and Meta-Analysis. J Pain Symptom Manage.2016;51(6):1070–90.
18Iacobucci G. Cancer survival in England: rates improve and variation falls. BMJ. 2019;365:l1532. Published 2019 Apr 2. doi:10.1136/bmj.l1532.
19Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2019 with focus on breast cancer. Ann Oncol. 2019;30(5):781-787. doi:10.1093/annonc/mdz051
20Malvezzi M, Carioli G, Bertuccio P, et al. European cancer mortality predictions for the year 2017, with focus on lung cancer. Ann Oncol. 2017;28(5):1117–23. doi:10.1093/annonc/mdx033
21Bouhnik A-D, Bendiane M-K, Cortaredona S, et al. The labour market, psychosocial outcomes and health conditions in cancer survivors: protocol for a nationwide longitudinal survey 2 and 5 years after cancer diagnosis (the VICAN survey). BMJ Open 2015;5: e005971. doi:10.1136/ bmjopen-2014-005971